Company Insights

CDXS customer relationships

Explore interactive graphBrowse insights index
CDXS customer relationship map

Codexis (CDXS) — Customer Relationships and Commercial Footprint

Codexis engineers and sells biocatalysts and enzyme platforms to large pharmaceutical and life‑science companies, monetizing through product sales (enzyme supply agreements), licensing fees, milestone and royalty streams, and collaboration services tied to its CodeEvolver/ECO Synthesis technologies. The company’s commercial footprint blends high‑value, recurring supply contracts for active pharmaceutical ingredient (API) manufacture with selective exclusive licenses and development collaborations that generate non‑cash R&D revenue and milestone payments. For a concise enterprise intelligence view, visit https://nullexposure.com/.

How Codexis converts science into revenue

Codexis’s commercial model is contracted and partner‑centric: large global pharmas procure optimized enzymes under multi‑year supply agreements or license engineered tools for in‑house development. Product sales can be lumpy but material—for example, historically a single supply agreement with Pfizer delivered tens of millions of dollars of product revenue in a single year—while licenses and royalties create longer‑tail upside. The business serves North America, EMEA and APAC with manufacturing and CDMO transfer validation as complementary commercialization vectors.

  • Contracting posture: mix of long‑term supply agreements and licensing deals, with some transactions recognized as non‑cash R&D revenue.
  • Counterparty profile: predominantly large enterprise pharmaceutical partners.
  • Revenue characteristics: concentrated and episodic revenue from a limited number of large customers alongside recurring manufacturing receipts.
  • Global reach: active commercial engagement across NA, EMEA and APAC.

Explore further company relationship signals and commercial risk mapping at https://nullexposure.com/.

The customer roster — relationship-by-relationship readout

Below are the customer and partner relationships identified in public filings and news, each summarized in plain English with source context.

Merck (MRK)

Codexis has an extended, decade‑long manufacturing collaboration with Merck providing an enzyme used in the commercial synthesis of sitagliptin for Januvia/Janumet; recent coverage notes an extension of the license and supply terms. According to FiercePharma (March 2026), Merck and Codexis reached a deal to extend their license and supply for the key sitagliptin enzyme (FY2021 context in reporting).

Pfizer (PFE)

Pfizer purchased proprietary Codexis enzymes used in the production of nirmatrelvir/PAXLOVID and executed enzyme supply and license agreements that have generated substantial product revenue and non‑cash license payments. News reporting and company disclosures note material product revenue from the Pfizer supply agreement and license credits recognized as R&D revenue (documented across FY2022–FY2024 filings and press coverage).

GSK (GSK)

GSK is cited in Codexis filings as one of several large performance enzyme customers whose termination would be a material risk, reflecting a commercial relationship as a major pharma counterparty. The FY2024 10‑K lists GSK among potential performance enzyme customers in the company’s customer concentration disclosure.

Novartis (NVS)

Novartis appears in company risk disclosures as a named performance enzyme customer whose contractual status is material to Codexis’s revenue mix, per the FY2024 10‑K language on customer termination risk.

Roche / Roche, Inc. (ROG / RHHBY)

Codexis has executed exclusive licensing for engineered DNA ligases with Roche and has announced a licensing agreement for newly engineered ligase technology, positioning Roche as a strategic licensee. Press reports and industry coverage (Globe and Mail and Nature reporting, FY2024–FY2025) document exclusive licenses and technology transfers dating back to 2019 and press release coverage in 2026.

Takeda Pharmaceuticals (TAK)

Takeda executed a strategic collaboration and license focused on CDX‑6311, establishing a development partnership announced in March 2020 and cited in later company‑level reporting. Nature and company materials capture the Takeda collaboration context (referenced in FY2025 reporting).

Tate & Lyle (TATE)

Codexis signed a multi‑year supply and licensing agreement with Tate & Lyle to supply performance enzymes for the manufacture of TASTEVA® M stevia sweetener, underscoring non‑pharma commercial applications. Prepared Foods reported the Tate & Lyle agreement in FY2019.

Nestlé Health Sciences (NESN)

Nestlé Health Sciences exercised an option and paid a milestone to acquire an exclusive license for CDX‑6114 following a prior development, option and licensing arrangement, evidencing food‑nutrition partner commercialization economics. Nature reporting records the option exercise and $3 million milestone (referenced in FY2019 disclosures and FY2025 summaries).

Molecular Assemblies, Inc.

Molecular Assemblies has been integrating Codexis enzymes with its chemistries to advance commercial processes, reflecting collaborative process development for novel molecular manufacturing. SynBioBeta coverage (FY2021) describes the collaboration.

Tate & Lyle (repeat)

(See above — included here in the roster for completeness based on original results.)

Bachem

Bachem participated in presentations validating transferability of Codexis ligation processes to CDMO in‑house facilities, demonstrating interest from established CDMOs in adopting Codexis methods. GlobeNewswire financial releases (Q2 2025) cite Bachem’s role in technical validation.

Nitto Avecia

Nitto Avecia is cited among CDMOs that validated transfer of Codexis ligation processes to in‑house manufacturing, supporting commercial scalability of the enzymatic process. GlobeNewswire (Q2 2025) includes Nitto Avecia in the validation cohort.

ST Pharm

ST Pharm likewise validated transferability of Codexis ligation processes in CDMO presentations, highlighting the company’s route to broaden manufacturing adoption through third‑party facilities. GlobeNewswire (Q2 2025) lists ST Pharm in these technical demonstrations.

Alphazyme

Codexis referenced potential royalty receipts under a license agreement with Alphazyme in its financial results, indicating a monetization channel via licensing royalties. GlobeNewswire (Q2 2025) mentions potential royalties from Alphazyme.

Axolabs

Axolabs signed an evaluation agreement to test Codexis’s ECO Synthesis platform for oligonucleotide therapeutics and to evaluate manufacturing capacity (January–November 2025 press coverage), showing momentum in RNA/oligo market validation. StockTitan and StockTwits articles (Jan–Nov 2025 / FY2026 reporting) document the evaluation agreement.

Shell

Codexis historically engaged with Shell on biomass‑to‑biofuels enzyme projects; the loss of that customer previously impacted revenue, illustrating historical concentration risk outside the pharma vertical. Nanalyze coverage (FY2022 retrospective) notes Shell as a former key customer whose departure affected revenues.

Operating constraints and risk signals investors must price

Codexis’s public disclosures and news coverage collectively establish a set of commercial constraints that define the investment thesis:

  • Licensing and supply mix is structural. Company filings describe licensing of the CodeEvolver platform in addition to enzyme supply agreements; licensing transactions have been recognized as non‑cash R&D revenue in specific instances (Pfizer license credits documented in 2023 and 2024 filings).
  • Counterparty concentration is material. Filings show a handful of customers represented a large share of revenue in recent years, with Pfizer alone accounting for a high single‑digit to mid‑double‑digit percentage of revenues depending on the year.
  • Global footprint and transferability. Revenue is distributed across NA, EMEA and APAC and Codexis has documented CDMO validation of process transfer to Bachem, Nitto Avecia and ST Pharm, supporting manufacturability scalability.
  • Customer profile and criticality. Many customers are large enterprises; Codexis supplies enzymes used in commercial APIs for approved drugs, giving the company a critical supplier role for specific products.
  • Maturity and spend band. The company reports mature, commercialized enzyme applications (16 approved therapeutic drugs) and historic product receipts in the $10–100M spend band for major supply agreements.

These constraints produce concentrated upside and concentrated downside: supply agreements and licenses produce outsized revenue when active, but termination or volume decline at a single large partner can materially affect financials.

For deeper customer and contract analytics, visit https://nullexposure.com/ to access cross‑reference intelligence.

Investment takeaways and next steps

Codexis combines high‑margin, science‑led licensing with material, but concentrated, manufacturing revenues—a profile that rewards product commercialization but exposes investors to counterparty and volume risk. The commercial roadmap into oligonucleotides and DNA ligation licensing with large partners like Roche and new CDMO validations supports revenue diversification, while legacy dependence on major supply contracts (e.g., Pfizer, Merck) defines headline volatility.

  • Bull case: expanding ECO Synthesis adoption across CDMOs and new license deals convert into steady royalties and recurring supply revenue.
  • Key risk: customer concentration and contract termination risk are explicit in company filings and press coverage.

To evaluate how these customer dynamics influence valuation and operational risk for CDXS, begin with a targeted risk mapping and scenario analysis on the Codexis customer book at https://nullexposure.com/.